ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Analysis of the efficacy of half-dose venetoclax combined with reduced-dose HA regimen in the induction therapy of acute myeloid leukemia].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We retrospectively analyzed clinical data on newly diagnosed acute myeloid leukemia (AML) patients who received HAV treatment between June 2020 and April 2023. The HAV regimen includes venetoclax at 100 mg on day 0 and 200 mg from day 1 to 14, administered orally; homoharringtonine at 2 mg/m(2) from day 3 to 9, given by intravenous infusion; and cytarabine at 50 mg/m(2) from day 3 to 9, also administered by intravenous infusion. Among 33 patients, 36.4% (12/33) were male, with a median age of 60 years (range, 14-67 years). The overall response rate after one cycle of induction therapy was 90.9%, and the complete response (CR) rate was 87.9%. Among the patients, 79.3% achieved CR with measurable residual disease negativity. No patient died during induction therapy. The median recovery times of neutrophils (≥1.0×10(9)/L) and platelets (≥30×10(9)/L) were 10 (5-12) days and 10 (3-13) days, respectively. Until October 30, 2024, the estimated 3-year overall survival rate, event-free survival rate, and disease-free survival rate were 68.2% (95%
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.